Dr Lal PathLabs buys 70% stake in SN Genelab for ₹168 crore
Dr Lal PathLabs is acquiring a 70% stake in genomics testing firm SN Genelab, strengthening its advanced diagnostics portfolio. The company expects the integration’s full financial contribution to reflect over the next two to three years.
What happened
Dr. Lal PathLabs · Dr Lal PathLabs will acquire a 70% stake in genomics testing firm SN Genelab for ₹168 crore, expanding its advanced diagnostics portfolio in
Key facts
- ₹168 crore acquisition value
- 70% stake in SN Genelab
- 47% stock gain over past six months
- ₹1,952 current share price
- 45-48 times FY28 estimated earnings
Why this matters
Dr Lal PathLabs is using a majority-stake acquisition to add genomics expertise and strengthen its advanced diagnostics portfolio, creating a platform for deeper integration and cross-selling.
What to watch
- Quarterly disclosure of SN Genelab revenue, test volumes, margins and integration costs.
- Evidence of genomics tests being added to Dr Lal's core catalogue, app, collection-centre network and corporate health packages.
- Management commentary on the timeline for material financial contribution and whether it remains within two to three years.
- Growth in oncology, reproductive genetics, prenatal screening and rare-disease testing demand.
- Competitive moves from Metropolis, SRL, hospital chains and specialised genomics laboratories.
- Changes in insurance coverage, employer benefits, clinical guidelines or regulation affecting genetic testing.
- Roll out SN Genelab test offerings across selected metro and tier-1 Dr Lal collection hubs before broader national distribution.
- Bundle genomics with oncology, reproductive-health, preventive-health and rare-disease diagnostic pathways.
- Invest in genetic counselling, clinician outreach, sample logistics and bioinformatics reporting to improve test conversion and repeat referrals.
- Pursue additional tuck-in acquisitions or technology partnerships in molecular diagnostics, pathology automation and specialty testing.
- Use the majority stake structure to retain SN Genelab's scientific team while standardising quality systems, procurement and back-office operations.